Study design & results
Available in the Gosset platform where reported.
Trial intelligence / Profile preview
Osimertinib in EGFR T790M+ NSCLC with Brain Metastases
NCT02972333Phase 3Unknown
- Sponsor
- Shandong Cancer Hospital
- Start
- Dec 2016
- Primary completion
- Sep 2019
- Modality
- Small Molecules
01
Overview
Phase 3, open-label, single-arm trial of osimertinib in non-small cell lung cancer (NSCLC) and brain metastases, sponsored by Shandong Cancer Hospital. Primary endpoint: Overall Progression-Free Survival at 2 years. Status: unknown.
02
Drugs
03
Conditions
non-small cell lung cancer (NSCLC)brain metastases
Beyond the preview
Go deeper on NCT02972333.
Study design, results and competitive context are available in the Gosset platform where reported.
Competitive context
Available in the Gosset platform where reported.
Bring the full picture into focus.
See how Gosset can support your research on NCT02972333.